

## ORIGINAL RESEARCH

# Outcomes of diabetic patients treated with dialysis: Complications and quality of life

<sup>1</sup>Dr. Amar Sultan, <sup>2</sup>Dr. Samarth Sharma, <sup>3</sup>Tejas Girish Karmarkar

<sup>1</sup>Assistant Professor, Department of Nephrology, Super Specialty Hospital, Akola, Maharashtra, India

<sup>2</sup>Associate Professor, Department of General Medicine, Shri Shankaracharya Institute of Medical Sciences, Bhilai, Chhattisgarh, India

<sup>3</sup>MBBS Student, Terna Medical College, Navi Mumbai, Maharashtra, India

### Corresponding author

Dr. Amar Sultan

Assistant Professor, Department of Nephrology, Super Specialty Hospital, Akola, Maharashtra, India

Received: 18 November, 2023

Accepted: 22 December, 2023

### ABSTRACT

**Background:** Diabetes is one of the most prevalent metabolic disorders affecting the population globally and affects multiple organ systems. Diabetes is also one of the most common causes of ESRD (end-stage renal disease) globally. **Aim:** The present study aimed to comparatively assess the outcomes in diabetic subjects managed with dialysis to non-diabetic subjects. **Methods:** The study assessed 266 hemodialysis maintenance subjects prospectively for 14 months. In all the included subjects, hemodialysis exit, hospitalization, and cause of death were assessed and compared to non-diabetic subjects. **Results:** In 266 subjects, diabetes was reported in 40.97% (n=109) subjects. In diabetic subjects, significantly worse SF36 scores, high LDL and serum triglycerides, lower iPTH, low serum albumin, high CRP, higher cardiovascular morbidities, lower dialysis duration, and higher age were seen compared to non-diabetic subjects. Hazard risk of death was 1.9 times higher in diabetics compared to non-diabetics. Death secondary to cardiovascular diseases with infection and other causes was 80% in diabetics and 54% in non-diabetics. The annual admission rate was also significantly higher in diabetics. **Conclusions:** The present study concludes that HRQOL (health-related quality of life) and clinical outcomes were much worse in diabetic subjects compared to non-diabetic subjects on hemodialysis which is primarily attributed to the higher frequency of cardiovascular diseases.

**Keywords:** Cardiovascular diseases, diabetes mellitus, hemodialysis, outcomes, quality of life

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

### INTRODUCTION

Diabetes is one of the most prevalent metabolic disorders affecting the population globally and affects multiple organ systems. Diabetes is also one of the most common causes of ESRD (end-stage renal disease) globally including in developing countries like India. In the United States alone, nearly 45% of End Stage Renal Diseases are attributed to the etiology of Diabetes mellitus.<sup>1</sup>

Diabetic nephropathy is defined as the presence of proteinuria which is more commonly seen in subjects with type 1 diabetes mellitus. However, subjects with type 2 diabetes mellitus also show the presence of proteinuria and diabetic nephropathy as complications of diabetes. Diabetic nephropathy is also seen in subjects presenting with secondary forms of diabetes mellitus such as subjects following pancreatectomy and pancreatitis when diabetes mellitus has a longer duration and glycemia level is high enough to proceed to diabetic complications.<sup>2</sup>

Nearly 25-30% of subjects with diabetes mellitus present micro microalbuminuria following a mean

duration of diabetes for 15 years and less than half of these subjects proceed to macroalbuminuria which is also known as overt nephropathy. Following the development of overt nephropathy, a considerable number of subjects develop ESRD (end-stage renal disease) at the rate of 4% to 17% at 20 years and nearly 17-30% after the initial diagnosis of diabetes mellitus and such subjects need hemodialysis for survival and maintenance of renal function.<sup>3</sup>

In recent times, the incidence of subjects that require diabetic nephropathy that require hemodialysis has reduced with the advancement of medical management of diabetes, particularly in developed countries. It can also be attributed to widespread education and the use of reno-protective measures in subjects with diabetes.<sup>4</sup>

In diabetic subjects on maintenance dialysis, the outcomes are worse compared to non-diabetic subjects having end-stage renal diseases secondary to glomerular diseases and hypertension depicting the marginal improvement following the recent literature data. The better outcomes of hemodialysis are seen in

young diabetic subjects with no cardiovascular diseases as comorbid factors.<sup>5</sup>

The present clinical study aimed to assess the death rate, comorbidities, quality of life, and characteristics in diabetic subjects on maintenance hemodialysis in the institute. The study also compared the outcomes and characteristics of hemodialysis diabetic subjects to non-diabetic subjects.

## MATERIALS AND METHODS

The present prospective clinical study aimed to comparatively assess the outcomes in diabetic subjects managed with dialysis to non-diabetic subjects. The study population was the subjects admitted to the institute and were on hemodialysis. Informed consent was taken from all the subjects in written and verbal format before study participation and after explaining the detailed study design to the participants.

The study included 266 subjects on maintenance hemodialysis who were from both genders. The inclusion criteria for the study were diabetic and non-diabetic subjects on maintenance hemodialysis for a minimum of 2 weeks, were of age 18 years or more, and gave consent for study participation. The exclusion criteria for the study were subjects that were not willing to participate in the study.

After final inclusion, detailed history was recorded from all the subjects followed by clinical examination. Also, the samples were collected for laboratory examination following the aseptic and sterile method of sample collection. A preformed structured questionnaire was made for all the subjects to collect demographic, clinical, and laboratory data for all the participants. The subjects were then followed for 14 months with the follow-up range of 15 days to 14 months. In all the study subjects, exit from the hemodialysis unit including death and cause of hospitalization was noted. The last follow-up was taken as the last visit or the time when the subject left the hemodialysis unit owing to transplantation, shift to peritoneal dialysis and renal recovery.

The subjects shifted to other wards and were followed there. The cardiovascular disease presence was assessed in all the subjects and the diagnosis of congestive heart failure was confirmed following the

echocardiographic criteria. CAD (coronary artery disease) was considered when subjects were on pharmacological management for CAD diagnosed with stress myocardial perfusion imaging, dobutamine stress echocardiography, or coronary angiography, PCI (percutaneous coronary intervention), or underwent CABG (coronary artery bypass graft).

HRQOL (health-related quality of life) was also assessed in all the subjects using the SF 36 (36-item short-form health survey) that assessed SF 36 scores and two dimensions and eight scales of MCS (mental component summary) and PCS (physical component summary) following the scoring algorithm.<sup>6,7</sup>

The data gathered were analyzed statistically using SPSS software version 21.0 (IBM Corp., Armonk, NY, USA) using the Fisher exact test and chi-square test to compare the categorical variables. To compare continuous variables, a t-test, ANOVA (analysis of variance), and Mann-Whitney U test was used. The hazard ratio was also assessed. The data were expressed in mean and standard deviation and frequency and percentage. The significance level was considered as  $p < 0.05$ .

## RESULTS

The present prospective clinical study aimed to comparatively assess the outcomes in diabetic subjects managed with dialysis to non-diabetic subjects. The study included 266 subjects on maintenance hemodialysis who were from both genders. Among 266 subjects, 109 were diabetics and 157 were non-diabetics. The mean age was significantly higher in diabetics at  $62.4 \pm 11.4$  years compared to  $53.3 \pm 16.5$  years in non-diabetics with  $p < 0.001$ . The gender has a non-significant difference in the two groups with  $p = 0.08$ . Hemodialysis vintage was significantly higher in non-diabetics with  $p = 0.01$ . Vascular access type was tunneled CVC in 22.01% ( $n = 24$ ) subjects with diabetes and 15.92% ( $n = 25$ ) in non-diabetics, AVG was used in 5.50% ( $n = 6$ ) diabetics and 7.64% ( $n = 12$ ) non-diabetics, and AVF in 69.72% ( $n = 76$ ) diabetics and 73.88% ( $n = 116$ ) non-diabetics respectively depicting non-significant difference with  $p = 0.17$ . BMI of  $> 25-30$  and  $> 30$  was significantly higher in diabetics compared to non-diabetics with  $p < 0.001$  as shown in Table 1.

**Table 1: Demographic data of study participants**

Characteristics	Diabetes (n=109)	Non-diabetes (n=157)	p-value
Mean age (years)	62.4±11.4	53.3±16.5	<0.001
<b>Gender</b>			
Males	58 (53.21)	94 (59.87)	0.08
Females	51 (46.78)	63 (40.12)	
Hemodialysis vintage <sup>2</sup>	21 (10-540)	28 (11-72)	0.01
<b>Vascular access type</b>			
Tunneled CVC	24 (22.01)	25 (15.92)	0.17
AVG	6 (5.50)	12 (7.64)	
AVF	76 (69.72)	116 (73.88)	
<b>BMI</b>			
≤18.5	3 (2.75)	9 (5.73)	<0.001

>18.5-25	50 (45.87)	96 (61.14)
>25-30	39 (35.77)	42 (26.75)
>30	17 (15.59)	10 (6.36)

Concerning the laboratory parameters, it was seen that single pool Kt/V was significantly higher in non-diabetics with  $1.31 \pm 0.19$  compared to diabetics where it was  $1.25 \pm 0.17$  with  $p=0.001$ . Creatinine levels were also significantly higher in non-diabetics with  $9.1 \pm 2.5$  compared to  $7.4 \pm 2.2$  in diabetics with  $p<0.001$ . CRP levels were significantly higher in diabetics compared to non-diabetics with  $p=0.001$ . However, albumin levels were significantly higher in non-diabetics with  $3.91 \pm 0.33$  g/L compared to  $3.84 \pm 0.33$ g/L with  $p<0.001$ . HDL was significantly higher in non-diabetics, whereas, LDL was significantly higher in

diabetics with  $p=0.03$  for both. Triglycerides in serum were also significantly higher in diabetics with  $p<0.001$ . iPTH was significantly higher in non-diabetics with 372 pg/mL compared to 270 pg/mL in diabetics with  $p<0.001$ . Phosphorus levels were significantly higher in non-diabetics with  $p=0.004$  as summarized in Table 2. Pre-dialysis BUN, Hemoglobin, calcium, potassium, cholesterol, ferritin, transferrin, iron, and alkaline phosphate levels in the serum of diabetics and non-diabetics showed statistically non-significant differences (Table 2).

**Table 2: Laboratory data in the study participants**

Laboratory parameters	Diabetes (n=109)	Non-diabetes (n=157)	p-value
Single pool Kt/V	$1.25 \pm 0.17$	$1.31 \pm 0.19$	0.001
Pre-dialysis BUN (mg/dl)	$56.0 \pm 12.9$	$56.3 \pm 13.5$	0.84
Creatinine (mg/dl)	$7.4 \pm 2.2$	$9.1 \pm 2.5$	<0.001
Hemoglobin (g/dL)	$10.4 \pm 1.2$	$10.4 \pm 1.4$	0.07
CRP (mg/L)	3.82 (1.52-8.32)	2.27 (0.92-5.15)	0.001
Albumin (g/L)	$3.84 \pm 0.33$	$3.91 \pm 0.33$	<0.001
Calcium (mg/dl)	$8.6 \pm 0.4$	$8.6 \pm 0.5$	0.95
Potassium (meq/L)	$5.0 \pm 0.4$	$4.9 \pm 0.4$	0.08
HDL (mg/dl)	$35.7 \pm 7.3$	$37.5 \pm 8.9$	0.03
LDL (mg/dl)	$82.3 \pm 24.3$	$77.3 \pm 23.6$	0.03
Cholesterol (mg/dL)	$151 \pm 33$	$145 \pm 36$	0.14
Triglycerides (mg/dL)	$165 \pm 89$	$137 \pm 65$	<0.001
Ferritin (ng/mL)	$405 \pm 245$	$444 \pm 293$	0.13
Transferrin ( $\mu$ g/dL)	$251 \pm 56$	$246 \pm 57$	0.43
Iron ( $\mu$ g/dL)	$66 \pm 37$	$69 \pm 33$	0.51
iPTH (pg/mL)	270 (148-418)	372 (171-705)	<0.001
Alkaline phosphatase (IU/L)	281 (211-363)	322 (197-447)	0.09
Phosphorus (mg/dL)	$5.0 \pm 0.9$	$5.4 \pm 1.0$	0.004

For the parameters of quality of life in study subjects, it was seen that the role-emotional component was significantly higher in non-diabetics with  $59.9 \pm 35.6$  compared to diabetics where it was  $50.3 \pm 34.9$  with  $p=0.007$ . Vitality, general health, role physical, physical functioning, SF 36 scores, mental component summary, physical component summary, and mental health were significantly higher in non-diabetic

subjects compared to diabetics with significant results and  $p=0.01, 0.02, 0.002, <0.001, <0.001, 0.004, 0.003,$  and  $0.04$  respectively. However, a non-significant difference was seen in social functioning and body pain in diabetics and non-diabetics with better results in non-diabetics and  $p=0.12$  and  $0.71$  respectively as shown in Table 3.

**Table 3: Quality of life components in diabetic and non-diabetic study subjects**

Quality of life parameters	Diabetes (n=109)	Non-diabetes (n=157)	p-value
Role-emotional	$50.3 \pm 34.9$	$59.9 \pm 35.6$	0.007
Social functioning	$47.7 \pm 29.0$	$52.5 \pm 30.2$	0.12
Vitality	$44.5 \pm 25.7$	$50.4 \pm 26.4$	0.01
General Health	$46.7 \pm 21.0$	$51.5 \pm 23.9$	0.02
Body pain	$60.2 \pm 31.7$	$61.3 \pm 31.0$	0.71
Role-physical	$43.0 \pm 30.5$	$52.2 \pm 30.5$	0.002
Physical functioning	$40.0 \pm 31.1$	$52.6 \pm 29.3$	<0.001
SF 36 score	$45.5 \pm 20.7$	$52.5 \pm 20.3$	<0.001
Mental component summary	$49.1 \pm 20.9$	$55.1 \pm 22.0$	0.004
Physical component summary	$46.9 \pm 21.6$	$53.6 \pm 21.4$	0.003

<b>Mental health</b>	55.9±27.5	61.1±25.3	0.04
----------------------	-----------	-----------	------

Cardiovascular diseases had a significantly higher prevalence in diabetics compared to non-diabetics where the clinical peripheral vascular disease was seen in 56.88% (n=62) diabetics and 0.63% (n=1) non-diabetic subjects with p<0.001. Cerebrovascular accidents were reported in 16.51% (n=18) diabetics and 7.64% (n=12) non-diabetics depicting a non-

significant difference with p=0.002. Congestive heart failure was seen in 36.69% (n=40) diabetics and 16.56% (n=26) non-diabetic subjects which was significantly higher in diabetics with p<0.001. Coronary artery disease (CAD) was significantly higher in diabetics compared to non-diabetics with p<0.001 (Table 4).

**Table 4: Cardiovascular diseases in diabetic and non-diabetic study subjects**

Cardiovascular comorbidities	Diabetes n=109 (%)	Non-diabetes n=157 (%)	p-value
<b>Clinical peripheral vascular disease</b>	62 (56.88)	1 (0.63)	<0.001
<b>Cerebrovascular accident</b>	18 (16.51)	12 (7.64)	0.002
<b>Congestive heart failure</b>	40 (36.69)	26 (16.56)	<0.001
<b>CAD</b>			
Stent	8 (7.33)	6 (3.82)	<0.001
Medical therapy	43 (39.44)	27 (17.19)	
None	39 (35.77)	112 (71.33)	
CABG	19 (17.43)	12 (7.64)	

The cause of exit in hemodialysis subjects was renal function recovery in 0.91% (n=1) diabetic and 0.63% (n=1) non-diabetic subjects. Peritoneal dialysis was the reason for exit from hemodialysis in 0.91% (n=1) diabetics and 1.27% (n=2) non-diabetics. Renal transplantation was caused in 6.42% (n=7) diabetics and 17.19% (n=27) non-diabetics. Death was the

cause for exit from hemodialysis in 41.28% (n=45) diabetics and in 22.29% (n=35) non-diabetics. Continued hemodialysis was caused in 50.45% (n=55) diabetics and 58.59% (n=92) non-diabetics. The difference was statistically significant in diabetics and non-diabetics with p<0.001 as depicted in Table 5.

**Table 5: Cause of exit from hemodialysis unit in diabetic and non-diabetic study subjects**

Causes of hemodialysis exit	Diabetes (n=109)	Non-diabetes (n=157)	p-value
<b>Renal function recovery</b>	1 (0.91)	1 (0.63)	<0.001
<b>Peritoneal dialysis</b>	1 (0.91)	2 (1.27)	
<b>Renal transplantation</b>	7 (6.42)	27 (17.19)	
<b>Death</b>	45 (41.28)	35 (22.29)	
<b>Continued hemodialysis</b>	55 (50.45)	92 (58.59)	

In 45 diabetics deaths and 35 non-diabetic deaths, the cause of death was cachexia with CVD (cardiovascular disease) or infection in 42.22% (n=19) diabetics and in 42.85% (n=15) non-diabetics. Death was because of malignancy in 13.33% (n=6) diabetics and 2.85% (n=1) non-diabetic subjects. Infection was the cause of death in 26.66% (n=12) diabetics and 8.57% (n=3) non-diabetics. Infections with CVD were the reported cause of death in 4.44%

(n=2) diabetics and 8.57% (n=3) non-diabetics. Another cause of CVD was the cause of death in 6.66% (n=3) of diabetics and 8.57% (n=3) of non-diabetics. CVD was the cause of death in 2.22% (n=1) diabetics and 8.57% (n=3) non-diabetics. Other unreported causes of death were reported in 4.44% (n=2) diabetics and 20% (n=7) non-diabetics as summarized in Table 6.

**Table 6: Cause of death in diabetic and non-diabetic study subjects**

Causes of Death	Diabetes (n=45)	Non-diabetes (n=35)
<b>Cachexia with CVD or infection</b>	19 (42.22)	15 (42.85)
<b>Malignancy</b>	6 (13.33)	1 (2.85)
<b>Infection</b>	12 (26.66)	3 (8.57)
<b>Infections with CVD</b>	2 (4.44)	3 (8.57)
<b>Others with CVD</b>	3 (6.66)	3 (8.57)
<b>CVD</b>	1 (2.22)	3 (8.57)
<b>Others</b>	2 (4.44)	7 (20)

## DISCUSSION

Among 266 study subjects, 109 were diabetics and 157 were non-diabetics. The mean age was significantly higher in diabetics at  $62.4 \pm 11.4$  years compared to  $53.3 \pm 16.5$  years in non-diabetics with  $p < 0.001$ . The gender has a non-significant difference in the two groups with  $p = 0.08$ . Hemodialysis vintage was significantly higher in non-diabetics with  $p = 0.01$ . Vascular access type was tunneled CVC in 22.01% ( $n = 24$ ) subjects with diabetes and 15.92% ( $n = 25$ ) in non-diabetics, AVG was used in 5.50% ( $n = 6$ ) diabetics and 7.64% ( $n = 12$ ) non-diabetics, and AVF in 69.72% ( $n = 76$ ) diabetics and 73.88% ( $n = 116$ ) non-diabetics respectively depicting non-significant difference with  $p = 0.17$ . BMI of  $>25-30$  and  $>30$  was significantly higher in diabetics compared to non-diabetics with  $p < 0.001$ . These data were similar to the studies of Sorensen V et al<sup>8</sup> in 2006 and Kaysen GA et al<sup>9</sup> in 2004 where authors assessed subjects with demographic data comparable to the present study.

It was seen that concerning the laboratory parameters, it was seen that single pool Kt/V was significantly higher in non-diabetics with  $1.31 \pm 0.19$  compared to diabetics where it was  $1.25 \pm 0.17$  with  $p = 0.001$ . Creatinine levels were also significantly higher in non-diabetics with  $9.1 \pm 2.5$  compared to  $7.4 \pm 2.2$  in diabetics with  $p < 0.001$ . CRP levels were significantly higher in diabetics compared to non-diabetics with  $p = 0.001$ . However, albumin levels were significantly higher in non-diabetics with  $3.91 \pm 0.33$  g/L compared to  $3.84 \pm 0.33$  g/L with  $p < 0.001$ . HDL was significantly higher in non-diabetics, whereas, LDL was significantly higher in diabetics with  $p = 0.03$  for both. Triglycerides in serum were also significantly higher in diabetics with  $p < 0.001$ . iPTH was significantly higher in non-diabetics with 372 pg/mL compared to 270 pg/mL in diabetics with  $p < 0.001$ . Phosphorus levels were significantly higher in non-diabetics with  $p = 0.004$ . Pre-dialysis BUN, Hemoglobin, calcium, potassium, cholesterol, ferritin, transferrin, iron, and alkaline phosphate levels in the serum of diabetics and non-diabetics showed statistically non-significant differences. These results were consistent with the previous studies of Hayashino Y et al<sup>10</sup> in 2009 and Ravelta KL et al<sup>11</sup> in 2004 where authors reported comparable laboratory parameters in their study subjects with diabetes and hemodialysis.

The study results showed that for the parameters of quality of life in study subjects, it was seen that the role-emotional component was significantly higher in non-diabetics with  $59.9 \pm 35.6$  compared to diabetics where it was  $50.3 \pm 34.9$  with  $p = 0.007$ . Vitality, general health, role physical, physical functioning, SF 36 scores, mental component summary, physical component summary, and mental health were significantly higher in non-diabetic subjects compared to diabetics with significant results and  $p = 0.01, 0.02, 0.002, < 0.001, < 0.001, 0.004, 0.003, \text{ and } 0.04$  respectively. However, a non-significant difference was seen in social functioning and body pain in

diabetics and non-diabetics with better results in non-diabetics and  $p = 0.12$  and  $0.71$  respectively. These findings were in agreement with the findings of Gumprecht J et al<sup>12</sup> in 2010 and Osthus TB et al<sup>13</sup> in 2012 where authors suggested similar quality of life in diabetics and non-diabetics on hemodialysis as seen in the results of the present study.

Concerning cardiovascular diseases had a significantly higher prevalence in diabetics compared to non-diabetics where the clinical peripheral vascular disease was seen in 56.88% ( $n = 62$ ) diabetics and 0.63% ( $n = 1$ ) non-diabetic subjects with  $p < 0.001$ . Cerebrovascular accidents were reported in 16.51% ( $n = 18$ ) diabetics and 7.64% ( $n = 12$ ) non-diabetics depicting a non-significant difference with  $p = 0.002$ . Congestive heart failure was seen in 36.69% ( $n = 40$ ) diabetics and 16.56% ( $n = 26$ ) non-diabetic subjects which was significantly higher in diabetics with  $p < 0.001$ . Coronary artery disease (CAD) was significantly higher in diabetics compared to non-diabetics with  $p < 0.001$ . These results were in line with previous studies of Ndip A et al<sup>14</sup> in 2010 and Morbach S et al<sup>15</sup> in 2001 where authors also reported a higher prevalence of cardiovascular diseases in diabetics on hemodialysis.

The study results showed that the cause of exit in hemodialysis subjects was renal function recovery in 0.91% ( $n = 1$ ) diabetic and 0.63% ( $n = 1$ ) non-diabetic subjects. Peritoneal dialysis was the reason for exit from hemodialysis in 0.91% ( $n = 1$ ) diabetics and 1.27% ( $n = 2$ ) non-diabetics. Renal transplantation was caused in 6.42% ( $n = 7$ ) diabetics and 17.19% ( $n = 27$ ) non-diabetics. Death was the cause for exit from hemodialysis in 41.28% ( $n = 45$ ) diabetics and in 22.29% ( $n = 35$ ) non-diabetics. Continued hemodialysis was caused in 50.45% ( $n = 55$ ) diabetics and 58.59% ( $n = 92$ ) non-diabetics. The difference was statistically significant in diabetics and non-diabetics with  $p < 0.001$ . These findings correlated with Dukkipati R et al<sup>16</sup> in 2010 and Ferreira A et al<sup>17</sup> in 2008 where authors suggested similar reasons for exit from hemodialysis as reported by the authors of the present study.

Concerning death, in 45 diabetics deaths and 35 non-diabetic deaths, the cause of death was cachexia with CVD (cardiovascular disease) or infection in 42.22% ( $n = 19$ ) diabetics and in 42.85% ( $n = 15$ ) non-diabetics. Death was because of malignancy in 13.33% ( $n = 6$ ) diabetics and 2.85% ( $n = 1$ ) non-diabetic subjects. Infection was the cause of death in 26.66% ( $n = 12$ ) diabetics and 8.57% ( $n = 3$ ) non-diabetics. Infections with CVD were the reported cause of death in 4.44% ( $n = 2$ ) diabetics and 8.57% ( $n = 3$ ) non-diabetics. Another cause of CVD was cause of death in 6.66% ( $n = 3$ ) in diabetics and 8.57% ( $n = 3$ ) non-diabetics. CVD was the cause of death in 2.22% ( $n = 1$ ) diabetics and 8.57% ( $n = 3$ ) non-diabetics. Other unreported causes of death were reported in 4.44% ( $n = 2$ ) diabetics and 20% ( $n = 7$ ) non-diabetics. These results were similar to the findings of Spasovski GB et al<sup>18</sup> in

2003 and Charra B et al<sup>19</sup> in 2001 where authors reported similar causes of death in diabetic subjects on hemodialysis.

## CONCLUSIONS

Considering its limitations, the present study concludes that HRQOL (health-related quality of life) and clinical outcomes were much worse in diabetic subjects compared to non-diabetic subjects on hemodialysis which is primarily attributed to the higher frequency of cardiovascular diseases.

## REFERENCES

1. CDC. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes--- the United States and Puerto Rico, 1996-2007 Disease Control. *MMWR Morb Mortal Wkly Rep.* 2010;59:1361–6.
2. Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991–2000) *Kidney Int.* 2005;67:1489–99.
3. Cano NJ, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P. et al. Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. *Kidney Int.* 2002;62:593–601.
4. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. *Am J Kidney Dis.* 1998;32:S118–S25.
5. Friedman AN, Fadem SZ. Reassessment of albumin as a nutritional marker in kidney disease. *J Am Soc Nephrol.* 2010;21:223–30.
6. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I Conceptual framework and item selection. *Med Care.* 1992;473–83.
7. Ware JE, Kosinski M, Keller S. SF-36 Physical and mental health summary scales: a user's manual: Health Assessment Lab; 1994.
8. Sørensen V, Hansen P, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. *Kidney Int.* 2006;70:187–91.
9. Kaysen GA, Dubin JA, Müller HG, Rosales L, Levin NW, Mitch WE. Inflammation and reduced albumin synthesis are associated with a stable decline in serum albumin in hemodialysis patients. *Kidney Int.* 2004;65:1408–15.
10. Hayashino Y, Fukuhara S, Akiba T, Akizawa T, Asano Y, Saito S. et al. Low health-related quality of life is associated with all-cause mortality in patients with diabetes on hemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. *Diabet Med.* 2009;26:921–7.
11. Revuelta KL, López FJG, de Alvaro Moreno F, Alonso J, Group C. Perceived mental health at the start of dialysis as a predictor of morbidity and mortality in patients with end-stage renal disease (CALVIDIA Study) *Nephrol Dial Transplant.* 2004;19:2347–53.
12. Gumprecht J, Żelobowska K, Gosek K, Żywiec J, Adamski M, Grzeszczak W. Quality of life among diabetic and non-diabetic patients on maintenance hemodialysis. *Exp Clin Endocrinol Diabetes.* 2010;118:205–8.
13. Osthus TB, von der Lippe N, Ribu L, Rustøen T, Leivestad T, Dammen T. et al. Health-related quality of life and all-cause mortality in patients with diabetes on dialysis. *BMC Nephrol.* 2012;13:78.
14. Ndip A, Rutter MK, Vileikyte L, Vardhan A, Asari A, Jameel M. et al. Dialysis treatment is an independent risk factor for foot ulceration in patients with diabetes and stage 4 or 5 chronic kidney disease. *Diabetes Care.* 2010;33:1811–6.
15. Morbach S, Quante C, Ochs HR, Gaschler F, Pallast J-M, Knevels U. Increased risk of lower-extremity amputation among Caucasian diabetic patients on dialysis. *Diabetes Care.* 2001;24:1689–90.
16. Dukkupati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM. et al. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. *J Ren Nutr.* 2010;20:243–54.
17. Ferreira A, Frazão JM, Monier-Faugere M-C, Gil C, Galvao J, Oliveira C. et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. *J Am Soc Nephrol.* 2008;19:405–12.
18. Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G. et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. *Nephrol Dial Transplant.* 2003;18:1159–66.
19. Charra B, VoVan C, Marcelli D, Ruffet M, Jean G, Hurot JM. et al. Diabetes mellitus in Tassin, France: remarkable transformation in incidence and outcome of ESRD in diabetes. *Adv Ren Replace Ther.* 2001;8:42–56.